



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service
Prior Authorization Criteria

Ingrezza™ (Valbenazine)
[Prior Authorization Request Form](#)

Effective 10/01/2017

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

Initial Prior Authorization Criteria:

1. Request must come from the treating neurologist or psychiatrist; **AND**
2. Patient must be at least 18 years of age; **AND**
3. Patient must have a documented clinical diagnosis of tardive dyskinesia meeting DSM-V criteria including:
 - a. Involuntary athetoid or choreiform movements
 - b. History of treatment with a dopamine receptor blocking agent (DRBA) such as an antipsychotic or metoclopramide
 - c. Symptom duration lasting at least 8 weeks

AND

4. Prescriber must submit the results of an Abnormal Involuntary Movement Scale (AIMS) exam; **AND**
5. Prescriber must submit documentation of all other therapies attempted. Unless contraindicated these therapies must include at least a 60-day trial each of **clonazepam** and **amantadine**. Patients with documentation of a previous benzodiazepine dependency are not required to trial clonazepam; **AND**
6. Patient must not be taking an MAOI (at least 14-days post-therapy), reserpine (must be >20 days post therapy) or any other concurrent VMAT 2 inhibitor.
7. Patient must not be currently pregnant or lactating.

Initial prior-authorization will be for 60 days.

Additional coverage requires clinical documentation indicating significant improvement in symptoms. The results of a current AIMS score must be submitted with every request.



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



References

- 1.) Lexi-Comp drug monograph for valbenazine (Reviewed 8/16/2017)
- 2.) Abnormal Involuntary Movement Scale (AIMS) and Extrapyrimalidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005 Sep 15;77(2-3):119-28. Gharabawi GM¹, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G.
- 3.) UpToDate Tardive Dyskinesia: Prevention and Treatment. Article last updated July 24, 2017
- 4.) American Academy of Neurology Evidence-based guideline: Treatment of tardive syndromes. July 29, 2013.